Diagnosing primary immunodeficiencies using protein-based screening assays

Clicks: 22
ID: 331489
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #29 of 46 articles by views in Clinical & Experimental Immunology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Primary immunodeficiencies (PIDs), now more commonly referred to as inborn errors of immunity (IEIs), are a diverse group of inherited conditions characterized by immune system defects, leading to recurrent infections, immune dysregulation, and autoimmune symptoms. Early diagnosis is crucial for effective management and treatment. This document explores the role of protein-based assays in diagnosing and characterizing IEIs. Protein-based assays, including enzyme-linked immunosorbent assay (ELISA), flow cytometry, and immunoblotting, have significantly advanced the identification and understanding of IEI. These assays enable rapid screening and functional analysis of immune proteins, providing critical insights into the phenotypic manifestations of genetic mutations. ELISA technology allows for the detection of specific antigens or antibodies, while flow cytometry facilitates the analysis of multiple cell populations and their functional states. Immunoblotting remains valuable for detecting protein expression and identifying truncated or non-functional proteins. This review highlights case studies demonstrating the application of these assays in diagnosing conditions such as X-linked lymphoproliferative syndrome type 2 (XLP2), activated phosphoinositide 3-kinase delta syndrome (APDS), Severe Combined Immunodeficiency (SCID) and Wiskott-Aldrich syndrome (WAS). It also discusses the importance of functional assays in confirming the pathogenicity of genetic variants of unknown significance (VUS) and guiding targeted genetic analysis. Overall, protein-based assays are essential tools in the diagnostic workflow for IEI, enabling timely and accurate diagnosis, guiding therapeutic decisions, and monitoring patient outcomes post-treatment, including hematopoietic stem cell transplantation (HSCT) and gene therapy.
Reference Key
openalex_W7220730940 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Micol Ferro, M Selby, M Davis, K Gilmour
Are you one of these authors? Claim your profile
Journal Clinical & Experimental Immunology
Year 2026
DOI
10.1093/cei/uxag062
URL
https://doi.org/10.1093/cei/uxag062
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.